Gulf Agriculture: Bayer advances genome-editing initiatives for nutrition enhanced vegetables

Gulf Agriculture: Bayer advances genome-editing initiatives for nutrition enhanced vegetables
07 June 2024

As part of its strategic open innovation approach, Bayer has embarked on two initiatives with external partners to advance genome editing in vegetables. In collaboration with South Korean biotech company G+FLAS, Bayer aims to develop genome-edited tomato varieties enriched with vitamin D3 to address global vitamin D deficiency, particularly prevalent in regions with limited winter sunlight, affecting approximately one billion people worldwide. Leveraging G+FLAS' genome editing technology and Bayer's tomato germplasm, the collaboration seeks to offer seeds for a broader range of tomato products, enhancing health benefits and resilience to climate change. JD Rossouw, Head of Vegetables Research & Development at Bayer, highlighted the commitment to delivering nutritious and flavorful foods, aligning with consumer preferences and addressing nutritional deficiencies. Additionally, Bayer has acquired a license from US-based startup Pairwise for genome-edited mustard greens, offering unique, high-nutrition leafy greens for the market. This strategic partnership underscores Bayer's open innovation approach, combining internal R&D capabilities with external expertise. Furthermore, Bayer has initiated an open innovation platform focusing on genome editing in fruits and vegetables, aiming to collaborate with academic researchers and companies to develop innovative products with increased nutritional content, environmental sustainability, and consumer appeal. These initiatives reflect Bayer's dedication to addressing global health and nutrition challenges through cutting-edge technology and collaboration.

Please find original version of article below:

The information shared by the Islamic Organization for Food Security (“IOFS”) on (the “Site”) serves solely for general informational purposes. As a non-profit international organization, IOFS provides this information in good faith, with no intention to commercialize, profit, or exploit any content. Commercial use, including reselling, charging for access, redistribution, or creating derivative works, such as unofficial translations based on these documents, is strictly prohibited. All posts, publications, texts, and any other information on the Site, owned by authors and references, are appropriately linked.

IOFS disclaims any liability for loss or damage of any kind resulting from the use of the Site. Your understanding and compliance with these terms contribute to maintaining the informative and non-commercial nature of our platform.